Última actualización 8 de julio de 2026
Key finding
Insulin lowered by ≥50% in 55/72 (76.39%) patients.
This pilot study evaluated a mobile insulin titration intervention for transitioning patients with Type 2 Diabetes from basal insulin to GLP-1 receptor agonists, showing promising outcomes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This pilot study evaluated a mobile insulin titration intervention for transitioning patients with Type 2 Diabetes from basal insulin to GLP-1 receptor agonists, showing promising outcomes.
This study highlights the potential of mobile health interventions in managing Type 2 Diabetes, particularly in transitioning patients to more effective treatments. By reducing reliance on insulin and promoting GLP-1 receptor agonists, it may enhance patient outcomes and adherence to treatment.
Non-randomized study design limits causal inference. Small sample size may affect generalizability. Lack of long-term follow-up data.
Published in
Publication details and source links for this paper.
Natalie L, Katie N, Sherlane B, et al. A Mobile Insulin Titration Intervention Using SMS Text Messaging to Transition Patients with Type 2 Diabetes from Basal Insulin to GLP-1 Receptor Agonists: A Pilot Study. JMIR Formative Research. 2026;10:e76993. doi:10.2196/76993
Insulin was reduced by at least 50% in 55 out of 72 patients (76.39%).
Insulin was completely stopped in 45 out of 72 patients (62.50%).
GLP-1 RA dose was increased by at least one level in 64 out of 72 patients (88.89%).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to GLP-1 receptor agonists and Hyperglycemia events, Percentage of SMS text message responses reporting hypoglycemia (<80 mg/dL), Percentage of patients discharged on maximum GLP-1 RA dose, and 3 more.
This study contributes evidence to
Primary intervention
GLP-1 receptor agonists
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
6
Evidence pairs
136
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_intervention_and_outcome
Evidencia relacionada
Tema de evidencia
Seguir evidencia
Core evidence
The primary outcomes reported in this study.
GLP-1 receptor agonists → Hyperglycemia events
GLP-1 receptor agonists → Hyperglycemia events
GLP-1 receptor agonists → Percentage of patients discharged on maximum GLP-1 RA dose
GLP-1 receptor agonists → Percentage of patients discharged on maximum GLP-1 RA dose
GLP-1 receptor agonists → Percentage of patients with GLP-1 RA dose increased by at least one level
GLP-1 receptor agonists → Percentage of patients with GLP-1 RA dose increased by at least one level
GLP-1 receptor agonists → Percentage of patients with insulin dose reduction by at least 50%
GLP-1 receptor agonists → Percentage of patients with insulin dose reduction by at least 50%
GLP-1 receptor agonists → Percentage of patients with insulin stopped completely
GLP-1 receptor agonists → Percentage of patients with insulin stopped completely
GLP-1 receptor agonists → Percentage of SMS text message responses reporting hypoglycemia (<80 mg/dL)
GLP-1 receptor agonists → Percentage of SMS text message responses reporting hypoglycemia (<80 mg/dL)
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Percentage of patients with GLP-1 RA dose increased by at least one level, GLP-1 Receptor Agonists and Hyperglycemia events.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring Hyperglycemia events
Measures Hyperglycemia events as a key outcome.
All studies measuring Percentage of patients with GLP-1 RA dose increased by at least one level
Measures Percentage of patients with GLP-1 RA dose increased by at least one level as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 receptor agonists appears to improve Percentage of patients discharged on maximum GLP-1 RA dose.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage of patients discharged on maximum GLP-1 RA dose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
GLP-1 receptor agonists appears to improve Percentage of patients with GLP-1 RA dose increased by at least one level.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage of patients with GLP-1 RA dose increased by at least one level
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
GLP-1 receptor agonists appears to improve Percentage of patients with insulin dose reduction by at least 50%.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage of patients with insulin dose reduction by at least 50%
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
GLP-1 receptor agonists appears to improve Percentage of patients with insulin stopped completely.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage of patients with insulin stopped completely
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Follow the topics this study contributes to.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.